These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28640433)

  • 1. Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 diabetes (GIFT study).
    Bajaj HS; Ye C; Jain E; Venn K; Stein E; Aronson R
    Diabetes Obes Metab; 2018 Jan; 20(1):195-199. PubMed ID: 28640433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial.
    Ji L; Li L; Kuang J; Yang T; Kim DJ; Kadir AA; Huang CN; Lee D
    Diabetes Obes Metab; 2017 May; 19(5):754-758. PubMed ID: 28075066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes.
    Gordon J; McEwan P; Evans M; Puelles J; Sinclair A
    Diabetes Obes Metab; 2017 May; 19(5):644-653. PubMed ID: 28026911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance.
    Benford M; Milligan G; Pike J; Anderson P; Piercy J; Fermer S
    Adv Ther; 2012 Jan; 29(1):26-40. PubMed ID: 22246944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
    Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany.
    Khunti K; Godec TR; Medina J; Garcia-Alvarez L; Hiller J; Gomes MB; Cid-Ruzafa J; Charbonnel B; Fenici P; Hammar N; Hashigami K; Kosiborod M; Nicolucci A; Shestakova MV; Ji L; Pocock S
    Diabetes Obes Metab; 2018 Feb; 20(2):389-399. PubMed ID: 28817227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.
    Smolen HJ; Murphy DR; Gahn JC; Yu X; Curtis BH
    J Manag Care Spec Pharm; 2014 Sep; 20(9):968-84. PubMed ID: 25166296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
    Hong SM; Park CY; Hwang DM; Han KA; Lee CB; Chung CH; Yoon KH; Mok JO; Park KS; Park SW
    Diabetes Obes Metab; 2017 May; 19(5):654-663. PubMed ID: 28058750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
    Fonseca V; Staels B; Morgan JD; Shentu Y; Golm GT; Johnson-Levonas AO; Kaufman KD; Goldstein BJ; Steinberg H
    J Diabetes Complications; 2013; 27(2):177-83. PubMed ID: 23116881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
    Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
    Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets.
    Duckworth W; Marcelli M; Padden M; Kellick K; Duhancik T; Wilhardt M; Colgan K; Romie A
    J Manag Care Pharm; 2003; 9(3):256-62. PubMed ID: 14613469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P; Sugimoto D; Vlajnic A; Kilo C
    J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
    Del Prato S; Taskinen MR; Owens DR; von Eynatten M; Emser A; Gong Y; Chiavetta S; Patel S; Woerle HJ
    J Diabetes Complications; 2013; 27(3):274-9. PubMed ID: 23403068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18,980 patients with type-2 diabetes mellitus--a meta-analysis.
    Liu X; Xiao Q; Zhang L; Yang Q; Liu X; Xu L; Cheng W
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):687-98. PubMed ID: 24639059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study.
    Ayvaz G; Keskin L; Akin F; Dokmetas HS; Tasan E; Ar IB; Uren E;
    Curr Med Res Opin; 2015 Apr; 31(4):623-32. PubMed ID: 25697921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2 diabetes and metabolic syndrome.
    Sicras-Mainar A; Navarro-Artieda R
    Diabetes Technol Ther; 2014 Nov; 16(11):722-7. PubMed ID: 25089916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
    Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
    Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.